Back to Journals » Biologics: Targets and Therapy » Volume 10

Emerging treatments in Castleman disease – a critical appraisal of siltuximab

Authors Koff J, Lonial S

Received 28 January 2015

Accepted for publication 21 May 2015

Published 25 January 2016 Volume 2016:10 Pages 9—15

DOI https://doi.org/10.2147/BTT.S60523

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Doris Benbrook

Jean L Koff, Sagar Lonial

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single-agent siltuximab treatment in CD, including the first-ever randomized clinical trial in this disease. Although much more work is needed to establish a standardized treatment approach, siltuximab appears to be a safe and effective treatment for patients with newly diagnosed and previously treated CD.

Keywords: treatment, lymphoma, interleukin-6

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]